WO2000056405A3 - Recepteur tr2 du facteur de necrose tumorale chez l'homme - Google Patents

Recepteur tr2 du facteur de necrose tumorale chez l'homme Download PDF

Info

Publication number
WO2000056405A3
WO2000056405A3 PCT/US2000/007521 US0007521W WO0056405A3 WO 2000056405 A3 WO2000056405 A3 WO 2000056405A3 US 0007521 W US0007521 W US 0007521W WO 0056405 A3 WO0056405 A3 WO 0056405A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptors
necrosis factor
tumor necrosis
methods
factor receptor
Prior art date
Application number
PCT/US2000/007521
Other languages
English (en)
Other versions
WO2000056405A2 (fr
Inventor
Jian Ni
Craig A Rosen
Reiner L Gentz
Original Assignee
Human Genome Sciences Inc
Jian Ni
Craig A Rosen
Reiner L Gentz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Jian Ni, Craig A Rosen, Reiner L Gentz filed Critical Human Genome Sciences Inc
Priority to EP00916583A priority Critical patent/EP1165185A2/fr
Priority to AU37667/00A priority patent/AU3766700A/en
Priority to JP2000606303A priority patent/JP2002540083A/ja
Priority to CA002365405A priority patent/CA2365405A1/fr
Publication of WO2000056405A2 publication Critical patent/WO2000056405A2/fr
Publication of WO2000056405A3 publication Critical patent/WO2000056405A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne de nouveaux membres de la famille des récepteurs du facteur de nécrose tumorale. L'invention concerne des molécules isolées d'acide nucléique codant un récepteur TR2 humain et deux variantes épissées dudit récepteur. L'invention concerne aussi des polypeptides TR2, ainsi que des vecteurs, cellules hôtes et procédés de recombinaison permettant de produire lesdits éléments. L'invention concerne également des méthodes de sélection permettant d'identifier des agonistes et antagonistes de l'activité du récepteur TR2. L'invention concerne en outre des méthodes diagnostiques pour dépister des pathologies liées à l'expression aberrante de récepteurs TR2, ainsi que des méthodes thérapeutiques pour traiter des pathologies liées à une prolifération ou différenciation aberrante de cellules exprimant des récepteurs TR2.
PCT/US2000/007521 1999-03-22 2000-03-22 Recepteur tr2 du facteur de necrose tumorale chez l'homme WO2000056405A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00916583A EP1165185A2 (fr) 1999-03-22 2000-03-22 Recepteur tr2 du facteur de necrose tumorale chez l'homme
AU37667/00A AU3766700A (en) 1999-03-22 2000-03-22 Human tumor necrosis factor receptor-like 2
JP2000606303A JP2002540083A (ja) 1999-03-22 2000-03-22 ヒト腫瘍壊死因子レセプター様２
CA002365405A CA2365405A1 (fr) 1999-03-22 2000-03-22 Recepteur tr2 du facteur de necrose tumorale chez l'homme

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12568399P 1999-03-22 1999-03-22
US12652299P 1999-03-26 1999-03-26
US13516999P 1999-05-20 1999-05-20
US14738399P 1999-08-06 1999-08-06
US60/125,683 1999-08-06
US60/126,522 1999-08-06
US60/135,169 1999-08-06
US60/147,383 1999-08-06

Publications (2)

Publication Number Publication Date
WO2000056405A2 WO2000056405A2 (fr) 2000-09-28
WO2000056405A3 true WO2000056405A3 (fr) 2001-01-04

Family

ID=27494596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007521 WO2000056405A2 (fr) 1999-03-22 2000-03-22 Recepteur tr2 du facteur de necrose tumorale chez l'homme

Country Status (5)

Country Link
EP (1) EP1165185A2 (fr)
JP (1) JP2002540083A (fr)
AU (1) AU3766700A (fr)
CA (1) CA2365405A1 (fr)
WO (1) WO2000056405A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068619A1 (en) * 2001-07-27 2003-04-10 Lal Preeti G. TNF receptor 2 related protein variant
WO2003011321A1 (fr) * 2001-07-31 2003-02-13 Genset S.A. Agonistes et antagonistes de la cobesine pour le traitement des troubles metaboliques
EP1875247B1 (fr) 2005-04-11 2011-02-02 Cambridge Enterprise Limited Modulation selective de recepteurs du facteur de necrose tumorale en therapie
WO2012048276A2 (fr) 2010-10-08 2012-04-12 Caridianbct, Inc. Procédés et systèmes configurables pour la culture et la récolte de cellules dans un système de bioréacteur à fibres creuses
CN105992816B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
EP3613841B1 (fr) 2014-03-25 2022-04-20 Terumo BCT, Inc. Remplacement passif de supports
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
CA2981304C (fr) * 2015-04-02 2024-01-02 Memorial Sloan Kettering Cancer Center Proteines de tnfrsf14/hvem et leurs procedes d'utilisation
WO2017004592A1 (fr) 2015-07-02 2017-01-05 Terumo Bct, Inc. Croissance cellulaire à l'aide de stimuli mécaniques
WO2017205667A1 (fr) 2016-05-25 2017-11-30 Terumo Bct, Inc. Expansion cellulaire
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002078A1 (fr) * 1989-08-07 1991-02-21 Peptide Technology Ltd Ligands de liaison du facteur de necrose de tumeurs
WO1997006251A1 (fr) * 1995-08-04 1997-02-20 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov, D.D. ANTICORPS MONOCLONAUX DIRIGES CONTRE LES RECEPTEURS SOLUBLES p55 ET p75 DU FACTEUR α DE NECROSE TUMORALE TNF-α DE MEME QUE CONTRE TNF-α ET SES ANALOGUES
WO1998051346A1 (fr) * 1997-05-12 1998-11-19 Smithkline Beecham Corporation Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002078A1 (fr) * 1989-08-07 1991-02-21 Peptide Technology Ltd Ligands de liaison du facteur de necrose de tumeurs
WO1997006251A1 (fr) * 1995-08-04 1997-02-20 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov, D.D. ANTICORPS MONOCLONAUX DIRIGES CONTRE LES RECEPTEURS SOLUBLES p55 ET p75 DU FACTEUR α DE NECROSE TUMORALE TNF-α DE MEME QUE CONTRE TNF-α ET SES ANALOGUES
WO1998051346A1 (fr) * 1997-05-12 1998-11-19 Smithkline Beecham Corporation Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FORRE O ET AL: "New treatment possibilities in rheumatoid arthritis.", SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, (2000) 29 (2) 73-84. REF: 113, XP000946746 *
KEYSTONE E C: "The role of tumor necrosis factor antagonism in clinical practice.", JOURNAL OF RHEUMATOLOGY, (1999 MAY) 26 SUPPL 57 22-8. REF: 20, XP000946828 *
KWON BYOUNG S ET AL: "A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 22, 1997, pages 14271 - 14276, XP002149343, ISSN: 0021-9258 *
WALLACE C A ET AL: "Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment.", JOURNAL OF RHEUMATOLOGY, (1993 JAN) 20 (1) 118-22., XP000946736 *

Also Published As

Publication number Publication date
WO2000056405A2 (fr) 2000-09-28
CA2365405A1 (fr) 2000-09-28
AU3766700A (en) 2000-10-09
EP1165185A2 (fr) 2002-01-02
JP2002540083A (ja) 2002-11-26

Similar Documents

Publication Publication Date Title
WO2000056405A3 (fr) Recepteur tr2 du facteur de necrose tumorale chez l'homme
WO1998031806A3 (fr) RECEPTEURS Fc ET POLYPEPTIDES
WO1998031818A3 (fr) Polypeptides semblables a tace ou a la matrilysime
WO1998030694A3 (fr) RECEPTEURS 6α ET 6β DU FACTEUR DE NECROSE TUMORALE
WO2001055307A8 (fr) Acides nucleiques, proteines et anticorps
AU9482498A (en) Interleukin-17 receptor-like protein
WO2001054472A8 (fr) Acides nucleiques, proteines et anticorps
WO2005001061A3 (fr) Polynucleotides codant pour de nouveaux variants du recepteur de l'adiponectine
WO2002086076A3 (fr) Polynucleotides et polypeptides associes au chemin nf-kb
WO2002072751A3 (fr) Polynucleotides codant une nouvelle metalloprotease, mp-1
WO2004039940A3 (fr) Polynucleotide codant pour des recepteurs couples aux proteines g, et leurs variantes d'epissage
WO2002083856A3 (fr) Polynucleotides codant deux nouveaux recepteurs couples aux proteines g, hgprbmy28 et hgprbmy29, et leurs variants d'epissage
WO2004100886A3 (fr) Polynucleotides et polypeptides associes a la voie nf-kb
WO2003027231A3 (fr) Polynucleotide codant pour une nouvelle proteine d'adaptation, pmn29, contenant le domaine d'homologie avec la pleckstrine et le domaine riche en proline
WO1998053069A3 (fr) Recepteurs du gdnf
WO2005003299A3 (fr) Polynucleotides codant de nouvelles proteines de liaison au guanylate (gbp)
WO2002072755A3 (fr) Polynucleotide codant un nouveau recepteur couple a la proteine g humaine, hgprbmy27
WO2001055168A8 (fr) Acides nucleiques, proteines, et anticorps
WO2003079746A3 (fr) Recepteur humain couple aux proteines g, hgprbmy14, associe au recepteur gpcr orphelin gpr73
WO2003083076A3 (fr) Polynucleotides codant pour deux nouveaux variants d'epissage d'une proteine de surface cellulaire humaine avec des plis d'immunoglobuline, bgs5g et bgs5i
IL155687A0 (en) Polynucleotides encoding hlrrsi1 polypeptides
WO2002086123A3 (fr) Nouveau recepteur couple a la proteine g humaine, le hgprbmy 11, a expression elevee dans le coeur et ses variants
WO2001005834A9 (fr) Recepteurs du facteur de necrose des tumeurs humain tr13 et tr14
WO2002046414A3 (fr) Hgprbmy23, nouveau recepteur d'origine humaine couple aux proteines g exprime fortement dans le rein
WO2002018622A3 (fr) Recepteurs du facteur de necrose tumorale 6$g(a) et 6$g(b)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 606303

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2365405

Country of ref document: CA

Ref country code: CA

Ref document number: 2365405

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000916583

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000916583

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916583

Country of ref document: EP